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Synovial sarcoma is a mesenchymal spindle cell tumor
with variable epithelial differentiation. Synovial sar-
coma, which accounts for 5–10% of soft tissue sar-
comas, occurs most commonly in the para-articular
tissues of the extremities. Approximately 90% of cases
occur before 50 years of age (most occur between 
15 and 30 years), but the tumor may occur in elderly
patients [1]. However, synovial sarcoma may arise in
various sites, including the head and neck, media-
stinum, heart, kidney, prostate, esophagus, and vulva
[2]. Histologically, synovial sarcoma is generally classi-
fied into four subtypes: (1) biphasic type, with distinct
epithelial and spindle cell components in varying pro-
portions; (2) monophasic fibrous type; (3) rare mono-
phasic epithelial type; (4) poorly differentiated (round
cell) type [3].
Primary sarcomas of the lung are rare, accounting
for less than 0.5% of primary lung cancers, and the
majority of malignant mesenchymal tumors of the lung
are metastases of a primary tumor elsewhere. Primary
pulmonary synovial sarcomas are extremely rare and
the diagnosis is made only after clinical and imaging
investigation to exclude alternative primary sources [4].
We describe a case of synovial sarcoma arising from
the lung, presenting as an asymptomatic lung tumor
and treated surgically by lobectomy of the lung; the
diagnosis was proven by SYT–SSX1 fusion gene tran-
scripts using reverse transcription–polymerase chain
reaction (RT–PCR). We also review the relevant English
literature.
CASE PRESENTATION
A 57-year-old man had a past medical history of
ischemic heart disease and diabetes under medical
control, as well as a history of operation for oral tumor
15 years previously. A mass in the right lower lobe of
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We report a rare case of primary synovial sarcoma of the lung. A 57-year-old man had a well-
defined tumor in the right middle lobe seen on chest computed tomography, and underwent
lobectomy. Grossly, the nonencapsulated tumor measured 4.5 cm in greatest diameter, with a
solid and tan-white cut surface. Histologically, the tumor was mainly composed of a dense proli-
feration of spindle cells. Immunohistochemical studies were focally positive for epithelial mem-
brane antigen, and diffusely positive for CD99 and Bcl-2. Cytokeratin, S-100 protein, desmin,
smooth muscle actin, and CD34 were absent. SYT-SSX1 gene fusion transcript was detected by
reverse transcription–polymerase chain reaction, which is diagnostic of primary synovial sarcoma
of the lung. We also review the literature with regard to the clinicopathologic, immunohisto-
chemical, and molecular studies of primary pulmonary synovial sarcoma.
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the lung was found incidentally on routine chest 
X-ray, and subsequent chest computed tomography
revealed a 4-cm well-defined mass occupying the
right middle lobe. Since a primary pulmonary tumor
was clinically suspected, right middle lobectomy
with lymph node dissection was performed.
Grossly, the tumor was relatively well circum-
scribed and nonencapsulated, measuring 4.5 × 3.2 ×
1.7 cm in size, and the cut surface was solid, whitish
in color and firm in consistency. Neither necrosis 
nor hemorrhage was found. Histologically, the tumor
showed interweaving fascicular spindle cell neo-
plasm with focal areas of dense hyaline fibrosis. A
hemangiopericytoma-like pattern was also noted.
The tumor cells were rather uniform with ovoid, pale
staining nuclei, and inconspicuous nucleoli. The cyto-
plasm was sparse and the cell borders were indistinct
(Figure 1). On immunohistochemistry, tumor cells
were negative for cytokeratin (DAKO, Copenhagen,
Denmark), but focally positive for epithelial membrane
antigen (DAKO). Vimentin (Biogenex, San Ramon, CA,
USA), CD99 (DAKO) and Bcl-2 (DAKO) were diffusely
Figure 1. Tumor shows interweaving fascicular spindle cell neo-
plasm with focal areas of dense hyaline fibrosis. Hemangiopericy-
toma-like pattern is also noted (left) (hematoxylin & eosin, H&E;
original magnification, 40×). Tumor cells are rather uniform with
ovoid, pale staining nuclei and inconspicuous nucleoli. The cyto-
plasm is sparse and the cell borders are indistinct. (Inset: H&E;
original magnification, 400×.)
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Figure 2. Tumor cells were: (A) focally positive (brown color) for epithelial membrane antigen; (B) diffusely positive for CD99; 
(C) negative for cytokeratin; (D) diffusely positive for Bcl-2.
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positive (Figure 2). However, S-100 protein (DAKO),
desmin (Biogenex), smooth muscle actin (Biogenex),
and CD34 (DAKO) were all negative. Histologic fea-
tures and immunohistochemical results were consis-
tent with the characteristics of synovial sarcoma of
monophasic type.
To detect characteristic chimeric fusion gene, 
SYT-SSX, RT–PCR assays were performed on RNA,
and demonstrated SYT-SSX1 fusion gene transcripts
(Figure 3) resulting from chromosomal translocation
t(X;18)(p11,q11) of typical synovial sarcoma.
Although no adjuvant treatment was given, there
was no recurrence during 6 months of postoperative
follow-up in the outpatient department.
DISCUSSION
Synovial sarcoma, which accounts for 5–10% of soft
tissue sarcomas, is not related to synovium. The tumor
is a mesenchymal spindle cell tumor with variable
epithelial differentiation. Although more than 80% of
synovial sarcomas arise in the deep soft tissues of the
extremities [3], it may also arise in other sites, including
the head and neck, mediastinum, heart, kidney, prostate,
esophagus, and vulva [2]. By application of immuno-
histochemical and molecular approaches including
detection of tumor-specific fusion genes, unusual sites
such as the lung have also been reported. To date,
approximately 50 cases of pulmonary synovial sarcoma
have been published in the English literature [5].
Pulmonary synovial sarcomas are located in
peripheral pulmonary parenchyma; they are well cir-
cumscribed but nonencapsulated solid tumors. Occa-
sionally, the tumor may diffusely infiltrate chest wall
or mediastinal structures. The size of the tumor ranges
from 0.6 to 20 cm and the cut surface of the tumor
shows cystic degenerative changes and necrosis [6].
The commonly reported symptoms of primary
pulmonary synovial sarcoma are chest pain, cough,
shortness of breath, and hemoptysis [7]. Low-grade
fever and weight loss are rare [6].
The generally accepted histologic subtypes of
synovial sarcoma are biphasic, monophasic fibrous,
monophasic epithelial, and poorly differentiated sub-
types [3], among which the monophasic neoplasm
subtype occurs most often in the lung [8]. The case
presented here had a monophasic fibrous subtype
composed solely of spindle cell component arranged
in interweaving fascicles. Hemangiopericytoma-like
pattern and focal hyaline fibrosis were also noted.
The differential diagnoses of pulmonary synovial
sarcoma include sarcomatoid carcinoma, sarcomatoid
variants of pleural mesothelioma, leiomyosarcoma,
hemangiopericytoma, malignant peripheral nerve
sheath tumor, fibrosarcoma, and spindle cell thymoma.
To exclude metastasis from an undetectable extrapul-
monary synovial sarcoma is of great importance [8,9].
No other synovial sarcoma has been detected in extra-
ordinary soft tissue previously.
Immunohistochemical studies often supplement
histology, since most synovial sarcomas show immuno-
reactivity for cytokeratin and/or epithelial membrane
antigen. Epithelial membrane antigen tends to be
expressed more often and widely than cytokeratin. In
monophasic lesions, reactivity may be scanty. Vimentin,
Bcl-2 and CD99 are frequently positive, while S-100
protein, desmin, smooth muscle actin and vascular
tumor markers are usually negative [6]. In our case,
immunohistochemistry results were as stated above
except for the negativity of cytokeratin.
Recently, histology and immunohistochemistry
have also been supplemented by molecular testing.
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Figure 3. Reverse transcription–polymerase chain reaction
demonstrates SYT-SSX1 fusion gene transcripts (forward primer
5AGACCAACACAGCCTGGACCAC3 for SSX1).
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Coindre et al concluded that molecular testing is not
required if the diagnosis of synovial sarcoma is certain
or probable on the basis of clinical, histologic, and
immunohistochemical evaluations [10]. While the
possibility of a diagnosis of synovial sarcoma is not
high, for example a monophasic subtype in uncom-
mon or unexpected sites, Coindre et al also con-
cluded that molecular testing can be very helpful or
even necessary [10]. Molecular testing of synovial
sarcomas reveals chromosomal translocation t(X;18)
(p11,q11). The translocation fuses the SYT gene from
chromosome 18 to either of two homologous genes at
Xp11, SSX1 or SSX2. For diagnosis, the sensitivity of
this examination is nearly 100%. Most biphasic tumors
are found to have an SYT-SSX1 fusion gene transcript
and most monophasic tumors have an SYT-SSX2 fusion
gene transcript [11]. In our case, detection of SYT-
SSX1 fusion gene transcript confirmed the diagnosis.
Trassard et al showed that synovial sarcoma was 
a high-grade malignancy with a high metastatic rate,
with 5- and 10-year survival rates of 24–76% and
11–56%, respectively. Factors for an unfavorable prog-
nosis were tumor size > 5 cm, male gender, greater age
(> 20 years), extensive tumor necrosis, high grade, 
a large number of mitotic figures (>10/10 high power
fields), neurovascular invasion [12], SYT-SSX1 variant
[13], and inadequate resection margin [14].
Although there is no standard therapy, most
authors have recommended extensive surgery in
addition to adjunctive radiotherapy with or without
adjunctive chemotherapy [3]. Although no adjuvant
treatment was given to our patient, there was no
recurrence over 6 months of postoperative follow-up
in the outpatient department. To our knowledge, this
is the first report of primary pulmonary synovial sar-
coma in Taiwan.
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